These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 26802027)
1. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences. Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027 [TBL] [Abstract][Full Text] [Related]
2. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse. Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191 [TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM; J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848 [TBL] [Abstract][Full Text] [Related]
5. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance. Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182 [TBL] [Abstract][Full Text] [Related]
6. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083 [TBL] [Abstract][Full Text] [Related]
8. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232 [TBL] [Abstract][Full Text] [Related]
9. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082 [TBL] [Abstract][Full Text] [Related]
10. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937 [TBL] [Abstract][Full Text] [Related]
11. Gain of 1q is a marker of poor prognosis in Wilms' tumors. Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N; Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759 [TBL] [Abstract][Full Text] [Related]
12. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177 [TBL] [Abstract][Full Text] [Related]
13. Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Perotti D; Spreafico F; Torri F; Gamba B; D'Adamo P; Pizzamiglio S; Terenziani M; Catania S; Collini P; Nantron M; Pession A; Bianchi M; Indolfi P; D'Angelo P; Fossati-Bellani F; Verderio P; Macciardi F; Radice P; Genes Chromosomes Cancer; 2012 Jul; 51(7):644-53. PubMed ID: 22407497 [TBL] [Abstract][Full Text] [Related]
14. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. Charles AK; Brown KW; Berry PJ Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048 [TBL] [Abstract][Full Text] [Related]
15. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group. Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061 [TBL] [Abstract][Full Text] [Related]
16. High-resolution molecular cytogenetic analysis of Wilms tumors highlights diagnostic difficulties among small round cell kidney tumors. Stewénius Y; Jin Y; Ora I; Panagopoulos I; Möller E; Mertens F; Sandstedt B; Alumets J; Akerman M; Merks JH; de Kraker J; Gisselsson D Genes Chromosomes Cancer; 2008 Oct; 47(10):845-52. PubMed ID: 18615675 [TBL] [Abstract][Full Text] [Related]
17. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382 [TBL] [Abstract][Full Text] [Related]
18. Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome. Haruta M; Arai Y; Okita H; Tanaka Y; Takimoto T; Sugino RP; Yamada Y; Kamijo T; Oue T; Fukuzawa M; Koshinaga T; Kaneko Y Neoplasia; 2019 Jan; 21(1):117-131. PubMed ID: 30530054 [TBL] [Abstract][Full Text] [Related]
19. Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster. Mengelbier LH; Karlsson J; Lindgren D; Øra I; Isaksson M; Frigyesi I; Frigyesi A; Bras J; Sandstedt B; Gisselsson D Am J Pathol; 2010 Nov; 177(5):2609-21. PubMed ID: 20847289 [TBL] [Abstract][Full Text] [Related]
20. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]